KR870008842A - N-[2-{[(2- 히드록시 페닐)(페닐)메틸렌]아미노}에틸]아세트아미드 유도체, 그의 제법 및 치료에의 응용 - Google Patents

N-[2-{[(2- 히드록시 페닐)(페닐)메틸렌]아미노}에틸]아세트아미드 유도체, 그의 제법 및 치료에의 응용 Download PDF

Info

Publication number
KR870008842A
KR870008842A KR870002176A KR870002176A KR870008842A KR 870008842 A KR870008842 A KR 870008842A KR 870002176 A KR870002176 A KR 870002176A KR 870002176 A KR870002176 A KR 870002176A KR 870008842 A KR870008842 A KR 870008842A
Authority
KR
South Korea
Prior art keywords
piperazinyl
piperidyl
group
halogen atom
atom
Prior art date
Application number
KR870002176A
Other languages
English (en)
Inventor
꼬마트몽 쟉끄
뤼르셀 토마스
자르드 리디아
Original Assignee
에뚜레 레메뜨르
신떼라보 소시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에뚜레 레메뜨르, 신떼라보 소시에떼 아노님 filed Critical 에뚜레 레메뜨르
Publication of KR870008842A publication Critical patent/KR870008842A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

내용 없음

Description

N-[2-{[(2-히드록시페닐)(페닐)메틸렌]아미노}에틸]아세트아미드 유도체, 그의 제법 및 치료에의 응용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 일반식(Ⅰ)에 해당하는 것을 특징으로 하는 순수한 광학 이성질체 또는 공학 이성질체의 혼합물 형태의 화합물, 뿐만 아니라 약리적으로 허용되는 산과의 그의 부과염.
    상기식에서,
    A와 B는 각각 수소원자를 나타내거나 또는 다르게는 함께 탄소-질소 결합을 나타내며,
    X1은 수소 또는 할로겐원자 또는(C1-C4) 알킬기를 나타내고,
    X2는 수소 또는 할로겐원자 또는 메틸기를 나타내며,
    X3는 수소 또는 할로겐원자 또는 히드록실기를 나타내고,
    X4는 수소 또는 할로겐원자를 나타내며,
    X5는 수소 또는 할로겐원자 또는 메틸 또는(C1-C4) 알킬술포닐기, 또는 할로겐원자 또는 메톡시기로 임의적으로 파라 치환된 벤질술포닐기를 나타내고,
    R은 1-모르폴리닐, 4-히드록시-1-피페리딜, 4-아미노 카르보닐-1-피페리딜, 4-히드록시-4-페닐-1-피페리딜, 4-(1-피페리딜)-1-피페리딜, 4-(2-옥소-1-벤조이미다졸리닐)-1-피페리딜, 1-피페라지닐, 4-메틸-1-피페라지닐, 4-에톡시카르보닐-1-피페라지닐, 4-페닐-1-피페라지닐, 4-클로로페닐-1-피페라지닐, 4-메틸페닐-1-피페라지닐, 또는4-(2-피리딜)-1-피페라지닐기를 나타낸다.
  2. 제 1 항에 있어서, A와 B는 함께 탄소-질소결합을 나타내고 R은 4-히드록시 피페리딜기를 나타내는 것을 특징으로 하는 화합물.
  3. 제 1 항과 제 2 항 중 어느 하나에 있어서, X1,X4및 X5는 각각 수소원자를 나타내고, X2는 염소원자 또는 메틸기를 나타내며,
    X3는 염소원자를 나타내는 것을 특징으로 하는 화합물.
  4. 일반식(Ⅱ)
    (여기서 X1,X2,X3,X4및 X5는 제 1 항에 기재된 바와 같다)의 벤조페논을 클로로포름과 같은 용매에서 및 환류온도에서 과량의 에틸렌 디아민과 반응시킨 다음, 얻은 화합물을 실온에서 염기의 존재하에 염화 2-클로로 아세틸과 반응시키고,
    다음에, 일반식(Ⅲ)
    의 얻은 화합물을 실온에서 또는 온화하게 가열하면서 저급알코올과 같은 용매에서 및 임의적으로 염기의 존재하에 일반식 RH(여기서 R은 제 1 항에 정의한 바와 같다)의 아민과 반응시키며, 만일 일반식(Ⅰ)에서, A와 B가 각각 수소원자를 나타낸다면 얻은 화합물을 실온에서 및 저급알코올과 같은 용매에서 알칼리금속의 수소화 붕소화물에 의해 환원시키는 것을 특징으로 하는 제 1 항에 정의된 화합물의 제조방법.
  5. 제 1 항 내지 제 3 항 중 어느 하나에 따르는 화합물로 구성되는 것을 특징으로 하는 의약 조성물.
  6. 제 1 항 내지 제 3 항 중 어느 하나에 따르는 화합물을 제약부형제와 조합하여 포함하는 것을 특징으로 하는 제약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870002176A 1986-03-12 1987-03-11 N-[2-{[(2- 히드록시 페닐)(페닐)메틸렌]아미노}에틸]아세트아미드 유도체, 그의 제법 및 치료에의 응용 KR870008842A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR86.03489 1986-03-12
FR8603489A FR2595695B1 (fr) 1986-03-12 1986-03-12 Derives de n-(((hydroxy-2 phenyl) (phenyl) methylene) amino-2) ethyl) acetamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
KR870008842A true KR870008842A (ko) 1987-10-21

Family

ID=9333030

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870002176A KR870008842A (ko) 1986-03-12 1987-03-11 N-[2-{[(2- 히드록시 페닐)(페닐)메틸렌]아미노}에틸]아세트아미드 유도체, 그의 제법 및 치료에의 응용

Country Status (12)

Country Link
EP (1) EP0239461A1 (ko)
JP (1) JPS62230767A (ko)
KR (1) KR870008842A (ko)
AU (1) AU6991087A (ko)
DK (1) DK123987A (ko)
FI (1) FI871067A (ko)
FR (1) FR2595695B1 (ko)
HU (1) HUT43820A (ko)
IL (1) IL81858A0 (ko)
NO (1) NO870998L (ko)
PT (1) PT84452B (ko)
ZA (1) ZA871766B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS103091A3 (en) * 1991-04-12 1992-10-14 Ustav Organicke Chemie A Bioch Protected substituted benzhydrylamines as shoulders for the synthesis ofpeptides on solid phase, process of their preparation and use
ES2165880T3 (es) * 1993-06-21 2002-04-01 Selectide Corp Conectores segmentables selectivamente basados en enlaces ester de acido iminodiacetico.
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) * 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
NZ500353A (en) 1997-04-14 2002-02-01 Cor Therapeutics Inc Cyclic diaza compounds that are selective inhibitors of factor Xa
US6369063B1 (en) 1997-04-14 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
AU747531B2 (en) * 1997-04-14 2002-05-16 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
AU741099B2 (en) * 1997-04-14 2001-11-22 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
EP1611116A2 (en) * 2003-04-08 2006-01-04 Neuromed Technologies, Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
FR2516509B1 (fr) * 1981-11-18 1985-07-26 Synthelabo Derives benzylideniques, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
IL81858A0 (en) 1987-10-20
FR2595695A1 (fr) 1987-09-18
PT84452A (fr) 1987-04-01
HUT43820A (en) 1987-12-28
DK123987D0 (da) 1987-03-11
DK123987A (da) 1987-09-13
FI871067A (fi) 1987-09-13
JPS62230767A (ja) 1987-10-09
ZA871766B (en) 1987-09-01
FI871067A0 (fi) 1987-03-11
FR2595695B1 (fr) 1988-12-02
NO870998L (no) 1987-09-14
AU6991087A (en) 1987-09-17
EP0239461A1 (fr) 1987-09-30
PT84452B (fr) 1989-03-17
NO870998D0 (no) 1987-03-11

Similar Documents

Publication Publication Date Title
KR870008842A (ko) N-[2-{[(2- 히드록시 페닐)(페닐)메틸렌]아미노}에틸]아세트아미드 유도체, 그의 제법 및 치료에의 응용
AU620401B2 (en) Pyridonecarboxylic acids and antibacterial agents
KR920021535A (ko) 다환 아민 화합물 및 그의 거울상 이성질체, 그의 제조방법 및 이를 함유하는 제약학적 조성물
HUP9900351A2 (hu) 2-(4-Helyettesített)-benzilamino-2-metil-propánamidszármazékok, előállításuk és a vegyületeket tartalmazó gyógyszerkészítmények
KR960034205A (ko) 피페리딘 유도체와 그것의 제조방법 및 치료적 이용
NO973243L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av gynekologiske sykdommer
KR920008033A (ko) 2-아미노피리미딘-4-카복사미드 유도체, 그들의 제법 및 치료적 용도
KR920019746A (ko) 신규한 시클로헥실벤즈아미드 유도체, 그의 제조방법 및 약제로서의 용도
DE69207301T2 (de) Substituierte 3-Piperazinylalkyl 2,3-Dihydro-4H-1,3-Benzoxazin-4-One, deren Herstellung und Verwendung in Heilkunde
FI101376B1 (fi) Menetelmä 3-bentsyyliamino-2-fenyylipiperidiinijohdannaisten valmistamiseksi
KR960022472A (ko) 3-페닐이소퀴놀-1(2h)-온 유도체와 그것의 제법 및 치료학적 이용
KR930000505A (ko) 2-(1-피페리딜) 에탄올 유도체, 그의 제법 및 치료학적 적용
KR950701332A (ko) 세로토닌 5HT₂길항제로서의 4-이미도메틸-1-[2'페닐-2'옥소에틸-]피페리딘, 이의 제조방법 및 치료에서의 용도(4-Imidomethyl-1-[2'phenyl-2'oxoethyl-] piperidines as serotonin 5HT₂-antagonists, their preparation and use in therapy)
IL82541A (en) 4(5)-substituted imidazole derivatives,intermediates thereof,processes for their preparation and pharmaceutical compositions containing them
KR890017244A (ko) 6-페닐-3-(피페라지닐알킬)-2,4-(1h,3h)-피리미딘디온 유도체, 그의 제법 및 치료에의 이용
SE7501365L (ko)
IE55328B1 (en) Ethers and oxime-ethers of alkylaminoalcohols as medicaments and novel products,and processes for their preparation
HUT50327A (en) Process for producing 2-square brackets open /piperidin-4-yl/-methyl square brackets closed-1,2,3,4-tetrahydro-isoquinoline derivatives and pharmaceutical compositions comprising same
JPS63290868A (ja) ジケトピペラジン誘導体およびその塩類
KR910002846A (ko) 쿠마린 유도체, 그의 제조방법 및 그의 뇌혈관 질환 치료에의 용도
ATE23337T1 (de) Chromanverbindungen.
KR920002517A (ko) 칼모둘린 억제 특성을 갖는 벤즈히드릴 유도체 및 그의 제조방법
US3898230A (en) Sydnone imine compounds
KR930006003A (ko) 이미다졸릴메틸-피리딘류 화합물
AR017676A1 (es) Derivado seudopolimorfico de dihidrocloruro del acido 2-[2-[4-[bis(4-fluorofenil)metil]-1-piperazinil]etoxi]acetico, procedimiento para su preparacion y composicion farmaceutica que lo comprende

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid